Antagonist Binding Characteristics of the Ser311→Cys Variant of Human Dopamine D2Receptorin Vivoandin Vitro (original) (raw)

1997, Biochemical and Biophysical Research Communications

Abstract

tor changes has extensively been explored (2-6). Three We report in vivo and in vitro antagonist binding relatively rare naturally occurring nucleotide variants characteristics of the naturally occurring Ser 311 rCys predicting an altered amino acid sequence have been variant of the human D 2 dopamine receptor. Striatal identified in the D 2 receptor gene (5,6). The allelic frereceptor binding characteristics in vivo were meaquencies of the amino acid substitutions in Caucasians sured with positron emission tomography and the D 2 are 0.014 for Ser 311 rCys and 0.001 for Pro 310 rSer subantagonist [ 11 C]raclopride. The in vitro affinity of stitutions, respectively. Additionally, one subject heterraclopride for the Ser 311 rCys variant and the wild type otsygous for Val 96 rAla substitution has been detected receptor was studied in membrane binding assays in a sample of 380 Caucasians (5).

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (24)

  1. Asherson, P., Williams, N., Roberts, E., McGuffin, M., and Owen, affect sequestration of D 2 receptor (17). If the replace- M. (1994) Lancet 343, 1045.
  2. Hattori, M., Nanko, S., Dai, X. Y., Fukuda, R., and Kazamatsuri, loop of the D 2 receptor affects G-protein coupling or H. (1994) Biochem. Biophys. Res. Commun. 202, 757-763.
  3. sequestration, this could result in an adaptive response 10. Laurent, C. S., Bdeau-Pean, D., Campion, T., d'Amato, M., Jay, in ligand-receptor recognition in vivo. However, this S., Dollfus, F., Thibaul, M., Petit, D., Samolyk, M., Martinez, appeared not to be the case in our PET study. Alterna- M., and Mallet, J. (1994) Psychiatr. Genet. 4, 229-230.
  4. tively, it might be that both alleles need to be affected 11. Crawford, F., Hoyne, J., Diaz, P., Osborne, A., Dorotheo, J., Shee- han, D., and Mullan, M. (1995) Am. J. Med. Genet. 60, 332-334.
  5. Craddock, N., Roberts, Q., Williams, N., McGuffin, P., and Owen, would be interesting, therefore, to measure the binding M. J. (1995) Psychiatr. Genet. 5, 63-65. characteristics for a Cys 311 homozygote.
  6. Arinami, T., Itokawa, M., Enguchi, H., Tagaya, H., Yano, S., In conclusion, our data indicate that the heterozy- Shimizu, H., Hagamuchi, H., and Toru, M. (1994) Lancet 343, gous Ser 311 rCys substitution of the D 2 dopamine recep- 703-704. tor is not associated with altered D 2 dopamine receptor 14. Higuchi, S., Muramatsu, T., Murayama, M., and Hayashida, M. binding density or apparent affinity in vivo. Further- (1994) Biochem. Biophys. Res. Commun. 204, 1199-1205.
  7. more, Ser 311 rCys substitution does not produce a 15. Shaikh, S., Collier, D., Arrnaz, M., Ball, D., Gill, M., and Kerwin, R. (1994) Lancet 343, 1045-1046.
  8. change in binding affinity for raclopride in vitro.
  9. Cravchik, A., Sibley, D. R., and Gejman, P. V. (1996) J. Biol. Chem. 271, 26013-26017.
  10. REFERENCES 20. Rinne, J. O., Hietala, J., Ruotsalainen, U., Sako, E., Laihinen, A., Na ˚gren, K., Lehikoinen, P., Oikonen, V., and Syva ¨lahti, E.
  11. Sibley, D. R., and Monsma, F. J. (1992) Trends. Pharmacol. Sci. (1993) J. Cereb. Blood Flow. Metab. 13, 310-314.
  12. Grandy, D. K., Marchionni, M. A., Makam, H., Stofko, R. E., Al- fano, M., Frothingham, Fischer, J. B., Burke-Howie, K. J., Bun-
  13. Sarkar, G., Kapelner, S., Grandy, D. K., Marchionni, M., Civelli, zow, J. R., Server, A. C., and Civelli, O. (1989) Proc. Natl. Acad.
  14. O., Sobell, J., Heston, L., and Sommer, S. S. (1991) Genomics Sci. USA 86, 9762-9766.
  15. Selbie, L. A., Hayes, G., and Shine, J. (1989) DNA 8, 683-689.
  16. Catalano, M., Nobile, M., Novelli, E., and Smeraldi, E. (1992) Neuropsychobiology 26, 1-3.
  17. Dal Toso, R., Sommer, B., Ewert, M., Herb, A., Pritchett, D. B., Bach, A., Shivers, B. D., and Seeburg, P. H. (1989) Embo J. 8,
  18. Seeman, P., Ohara, K., Ulpian, C., Seeman, M. V., Jellinger, K., 4025-4034.
  19. Van Tol, H. H. M., and Niznik, H. B. (1993) Neuropsychophar- macology 8, 137-142.
  20. O'Malley, K. L., Mack, K. J., Gandelman, K-Y, and Todd, R. D. (1990) Biochem. 29, 1367-1371.
  21. Gejman, P. V., Ram, A., Gelernter, J., Friedman, E., Cao, Q., 25. Gandelman, K-Y., Harmon, S., Todd, R. D., and O'Malley, K. L. Pickar, D., Blum, K., Noble, E. P., Kranzler, H. R., O'Malley, S., (1991) J. Neurochem. 56, 1024-1029.
  22. Hamer, D. H., Whitsitt, F., Rao, P., DeLisi, L. E., Virkkunen, M., Linnoila, M., Goldman, D., and Gershon, E. S. (1994) Jama 271, 26. Roberts, D. A., Balderson, D., Pickering-Brown, S. M., Deakin, 204-208. J. F. W., and Owen, F. (1994) Mol. Brain. Res. 25, 173-175.
  23. Itokawa, M., Arinami, T., Futamura, N., Hamaguchi, H., and 27. McVittie, L. D., Ariano, M. A., and Sibley, D. R. (1991) Proc. Natl. Toru, M. (1993) Biochem. Biophys. Res. Commun. 196, 1369- Acad. Sci. USA 88, 1441-1445. 1375. 28. Leysen, J. E., Gommeren, W., Mertens, J., Luyten, W. H. M. L., Pauwels, P. J., Ewert, M., and Seeburg, P. (1993) Psychopharma-
  24. Nanko, S., Hattori, M., Dai, X. Y., Fukuda., R., and Kazamatsuri, H. (1994) Lancet 343, 1044. cology 110, 27-36.